Iatrogenic immunosuppression and risk of non-Hodgkin lymphoma in solid organ transplantation: A population-based cohort study in Australia

British Journal of Haematology

Volumn 174, Issue 4, 2016, Pages 550-562

  Na, Renhua ^a   Laaksonen, Maarit A ^a   Grulich, Andrew E ^b   Meagher, Nicola S ^a   McCaughan, Geoffrey W ^c   Keogh, Anne M ^d   Vajdic, Claire M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

Author keywords

cohort; immunosuppression; non Hodgkin lymphoma; risk; transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID; OKT 3; TACROLIMUS;

ADULT; ADVANCED CANCER; AGE; ARTICLE; AUSTRALIA; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EARLY CANCER; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NONHODGKIN LYMPHOMA; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION;

EID: 84982985663     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14083     Document Type: Article

References (49)

1. Adami, J., Gabel, H., Lindelof, B., Ekstrom, K., Rydh, B., Glimelius, B., Ekbom, A., Adami, H.O. & Granath, F. (2003) Cancer risk following organ transplantation: a nationwide cohort study in Sweden. British Journal of Cancer, 89, 1221–1227.
2. Beatty, P.R., Krams, S.M., Esquivel, C.O. & Martinez, O.M. (1998) Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. Transplantation, 65, 1248–1255.
3. Bernatsky, S., Lee, J.L. & Rahme, E. (2007) Non-Hodgkin's lymphoma—meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories. Rheumatology, 46, 690–694.
4. Bucks, C.M., Norton, J.A., Boesteanu, A.C., Mueller, Y.M. & Katsikis, P.D. (2009) Chronic antigen stimulation alone is sufficient to drive CD8 + T cell exhaustion. Journal of Immunology, 182, 6697–6708.
5. Bugelski, P.J., Volk, A., Walker, M.R., Krayer, J.H., Martin, P. & Descotes, J. (2010) Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia. International Journal of Toxicology, 29, 435–466.
6. Bustami, R.T., Ojo, A.O., Wolfe, R.A., Merion, R.M., Bennett, W.M., McDiarmid, S.V., Leichtman, A.B., Held, P.J. & Port, F.K. (2004) Immunosuppression and the risk10 of post-transplant malignancy among cadaveric first kidney transplant recipients. American Journal of Transplantation, 4, 87–93.
7. Caillard, S., Dharnidharka, V., Agodoa, L., Bohen, E. & Abbott, K. (2005) Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation, 80, 1233–1243.
8. Caillard, S., Lelong, C., Pessione, F. & Moulin, B. for the French, PTLD Working Group. (2006) Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. American Journal of Transplantation, 6, 2735–2742.
9. Caillard, S., Lamy, F.X., Quelen, C., Dantal, J., Lebranchu, Y., Lang, P., Velten, M. & Moulin, B. (2012) Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the french registry and analysis of subgroups of lymphomas. American Journal of Transplantation, 12, 682–693.
10. Chalastanis, A., Penard-Lacronique, V., Svrcek, M., Defaweux, V., Antoine, N., Buhard, O., Dumont, S., Fabiani, B., Renault, I., Tubacher, E., Fléjou, J.-F., te Riele, H., Duval, A. & Muleris, M. (2010) Azathioprine-induced carcinogenesis in mice according to msh2 genotype. Journal of the National Cancer Institute, 102, 1731–1740.
11. Cherikh, W.S., Kauffman, H.M., McBride, M.A., Maghirang, J., Swinnen, L.J. & Hanto, D.W. (2003) Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation, 76, 1289–1293.
12. Cockfield, S.M. (2001) Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transplant Infectious Disease, 3, 70–78.
13. Collett, D., Mumford, L., Banner, N.R., Neuberger, J. & Watson, C. (2010) Comparison of the incidence of malignancy in recipients of different types of organ: a UK registry audit. American Journal of Transplantation, 10, 1889–1896.
14. Crespo-Leiro, M.G., Alonso-Pulpon, L., Vazquez de Prada, J.A., Almenar, L., Arizon, J.M., Brossa, V., Delgado, J.F., Fernandez-Yanez, J., Manito, N., Rabago, G., Lage, E., Roig, E., Diaz-Molina, B., Pascual, D. & Muniz, J. (2008) Malignancy after heart transplantation: incidence, prognosis and risk factors. American Journal of Transplantation, 8, 1031–1039.
15. Dharnidharka, V.R., Lamb, K.E., Gregg, J.A. & Meier-Kriesche, H.U. (2012) Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR national registry data in the United States. American Journal of Transplantation, 12, 976–983.
16. Dotti, G., Fiocchi, R., Motta, T., Gamba, A., Gotti, E., Gridelli, B., Borleri, G., Manzoni, C., Viero, P., Remuzzi, G., Barbui, T. & Rambaldi, A. (2000) Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation, 69, 827–833.
17. Engels, E.A., Pfeiffer, R.M., Fraumeni, J.F., Kasiske, B.L., Israni, A.K., Snyder, J.J., Wolfe, R.A., Goodrich, N.P., Bayakly, A.R., Clarke, C.A., Copeland, G., Finch, J.L., Fleissner, M.L., Goodman, M.T., Kahn, A., Koch, L., Lynch, C.F., Madeleine, M.M., Pawlish, K., Rao, C., Williams, M.A., Castenson, D., Curry, M., Parsons, R., Fant, G. & Lin, M. (2011) Spectrum of cancer risk among US solid organ transplant recipients. Journal of the American Medical Association, 306, 1891–1901.
18. European Medicines Agency. (2010) Guideline on missing data in confirmatory clinical trials. Committee for Medicinal Products for Human Use. EMA/CPMP/EWP/1776/99. European Medicines Agency, London.
19. Faull, R.J., Hollett, P. & McDonald, S.P. (2005) Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation, 80, 193–197.
20. Fernberg, P., Edgren, G., Adami, J., Ingvar, Å., Bellocco, R., Tufveson, G., Höglund, P., Kinch, A., Simard, J.F., Baecklund, E., Lindelöf, B., Pawitan, Y. & Smedby, K.E. (2011) Time trends in risk and risk determinants of non-Hodgkin lymphoma in solid organ transplant recipients. American Journal of Transplantation, 11, 2472–2482.
21. Ghobrial, I.M., Habermann, T.M., Macon, W.R., Ristow, K.M., Larson, T.S., Walker, R.C., Ansell, S.M., Gores, G.J., Stegall, M.D. & McGregor, C.G. (2005) Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation, 79, 244–247.
22. Gibson, T.M., Engels, E.A., Clarke, C.A., Lynch, C.F., Weisenburger, D.D. & Morton, L.M. (2014) Risk of diffuse large B-cell lymphoma after solid organ transplantation in the United States. American Journal of Hematology, 89, 714–720.
23. Guiguet, M., Boué, F., Cadranel, J., Lang, J.-M., Rosenthal, E. & Costagliola, D. (2009) Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. The Lancet Oncology, 10, 1152–1159.
24. Heidt, S., Roelen, D.L., Eijsink, C., van Kooten, C., Claas, F.H. & Mulder, A. (2008) Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. Transplantation, 86, 1292–1300.
25. IARC. (1987) Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. World Health Organization, International Agency for Research on Cancer, Lyon, France. 7, 1–440.
26. IARC. (2012) Pharmaceuticals. Volume 100 A. A Review of Human Carcinogens. International Agency for Research on Cancer, Lyon, France. 1–401 pp.
27. Jaro, M.A. (1995) Probabilistic linkage of large public health data files. Statistics in Medicine, 14, 491–498.
28. Kinch, A., Baecklund, E., Backlin, C., Ekman, T., Molin, D., Tufveson, G., Fernberg, P., Sundström, C., Pauksens, K. & Enblad, G. (2014) A population-based study of 135 lymphomas after solid organ transplantation: the role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival. Acta Oncologica, 53, 669–679.
29. Knight, J.S., Tsodikov, A., Cibrik, D.M., Ross, C.W., Kaminski, M.S. & Blayney, D.W. (2009) Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. Journal of Clinical Oncology, 27, 3354–3362.
30. Kotlyar, D.S., Lewis, J.D., Beaugerie, L., Tierney, A., Brensinger, C.M., Gisbert, J.P., Loftus, E.V. Jr, Peyrin-Biroulet, L., Blonski, W.C., Van Domselaar, M., Chaparro, M., Sandilya, S., Bewtra, M., Beigel, F., Biancone, L. & Lichtenstein, G.R. (2014) Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clinical Gastroenterology and Hepatology, 13, 847–858.
31. van Leeuwen, M.T., Grulich, A.E., Webster, A.C., McCredie, M.R., Stewart, J.H., McDonald, S.P., Amin, J., Kaldor, J.M., Chapman, J.R. & Vajdic, C.M. (2009) Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood, 114, 630–637.
32. Mistrikova, J., Mrmusova, M., Durmanova, V. & Rajcani, J. (1999) Increased neoplasm development due to immunosuppressive treatment with FK-506 in BALB/C mice persistently infected with the mouse herpesvirus (MHV-72). Viral Immunology, 12, 237–247.
33. Na, R., Grulich, A.E., Meagher, N.S., McCaughan, G.W., Keogh, A.M. & Vajdic, C.M. (2013a) Comparison of de novo cancer incidence in Australian liver, heart and lung transplant recipients. American Journal of Transplantation, 13, 174–183.
34. Na, R., Grulich, A.E., Meagher, N.S., McCaughan, G.W., Keogh, A.M. & Vajdic, C.M. (2013b) De novo cancer-related death in Australian liver and cardiothoracic transplant recipients. American Journal of Transplantation, 13, 1296–1304.
35. Na, R., Laaksonen, M.A., Grulich, A.E., Webster, A.C., Meagher, N.S., McCaughan, G., Keogh, A. & Vajdic, C.M. (2015) Longitudinal dose and type of immunosuppression in a national cohort of Australian liver, heart and lung transplant recipients, 1984–2006. Clinical Transplantation, 29, 978–990.
36. Nguyen, T., Vacek, P.M., O'Neill, P., Colletti, R.B. & Finette, B.A. (2009) Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease. Cancer Research, 69, 7004–7012.
37. Opelz, G. & Dohler, B. (2004) Lymphomas after solid organ transplantation: a collaborative transplant study report. American Journal of Transplantation, 4, 222–230.
38. Opelz, G., Daniel, V., Naujokat, C., Fickenscher, H. & Dohler, B. (2007) Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncology, 8, 212–218.
39. Opelz, G., Daniel, V., Naujokat, C. & Dohler, B. (2009) Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation, 88, 962–967.
40. OPTN/SRTR. (2012) Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients 2011 annual data report. US Department of Health and Human Services, Rockville, MD.
41. Quinlan, S.C., Pfeiffer, R.M., Morton, L.M. & Engels, E.A. (2011) Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. American Journal of Hematology, 86, 206–209.
42. Rafferty, P., Egenolf, D., Brosnan, K., Makropoulos, D., Jordan, J., Meshaw, K., Walker, M., Volk, A. & Bugelski, P.J. (2012) Immunotoxicologic effects of cyclosporine on tumor progression in models of squamous cell carcinoma and B-cell lymphoma in C3H mice. Journal of Immunotoxicology, 9, 43–55.
43. Robson, R., Cecka, J.M., Opelz, G., Budde, M. & Sacks, S. (2005) Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. American Journal of Transplantation, 5, 2954–2960.
44. Sampaio, M.S., Cho, Y.W., Shah, T., Bunnapradist, S. & Hutchinson, I.V. (2012) Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. Transplantation, 93, 73–81.
45. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. IARC, Lyon.
46. Swinnen, L.J., Costanzo-Nordin, M.R., Fisher, S.G., O'Sullivan, E.J., Johnson, M.R., Heroux, A.L., Dizikes, G.J., Pifarre, R. & Fisher, R.I. (1990) Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. New England Journal of Medicine, 323, 1723–1728.
47. Turner, J.J., Morton, L.M., Linet, M.M.D., Clarke, C.A., E., K.M., Vajdic, C.M., Alain, M., Maynadie, M., Chiu, B.C., Rafael, M.-G., Seniori, C.A., Cerhan, J.R. & Weisenberger, D.D. (2010) InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood, 116, e90–e98.
48. Villeneuve, P.J., Schaubel, D.E., Fenton, S.S., Shepherd, F.A., Jiang, Y. & Mao, Y. (2007) Cancer incidence among Canadian kidney transplant recipients. American Journal of Transplantation, 7, 941–948.
49. Wiesner, R.H. & Fung, J.J. (2011) Present state of immunosuppressive therapy in liver transplant recipients. Liver Transplantation, 17, S1–S9.